Table 3.

Hazard ratios for disease-free survival and overall survival by baseline characteristics (Cox proportional hazards models)

Patient characteristics	Disease-free survival				Overall survival
	Univariate analysis		Multivariable analysis		Univariate analysis
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Race
Asian vs. Caucasian	1.49 (0.51–4.39)	0.47			1.62 (0.47–5.56)	0.45
Black vs. Caucasian	1.24 (0.42–3.64)	0.69			0.92 (0.31–2.75)	0.88
Hispanic vs. Caucasian	1.27 (0.57–2.80)	0.56			2.06 (0.75–5.68)	0.16
Age	1.004 (0.98–1.03)	0.78			1.00 (0.97–1.03)	0.99
AJCC Stage
II vs. III	2.01 (1.02–3.94)	0.04			1.98 (0.92–4.25)	0.08
Tumor grade
I/II vs. III	1.12 (0.55–2.27)	0.76			0.99 (0.45–2.19)	0.57
ER
Positive vs. Negative	1.29 (0.68–2.47)	0.44			0.83 (0.40–1.73)	0.62
PR
Positive vs. Negative	1.41 (0.72–2.77)	0.32			1.05 (0.50–2.20)	0.91
HR status
Positive vs. Negative	1.30 (0.68–2.47)	0.43	2.18 (1.10–4.33)	0.03	0.80 (0.38–1.69)	0.56
Her2 status
Positive vs. Negative	0.67 (0.32–1.43)	0.3			0.63 (0.27–1.49)	0.29
Pathologic response
pCR/pPR vs. pNR	2.85 (1.25–6.51)	0.01	4.08 (1.70–9.80)	0.002	4.27 (1.48–12.29)a	0.01

^aBest fit model chosen from stepwise selection procedures based on likelihood ratio criterion; only pathologic response influences survival when additional variables are included in overall survival models

HR hazard ratio, CI confidence interval, AJCC American Joint Commission on Cancer, ER estrogen receptor, PR progesterone receptor, HR hormone receptor, Her2 human epidermal growth factor receptor, pCR pathologic complete response, pPR pathologic partial response, pNR no pathologic response